0

    531210

    COLINZ

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    COLINZ LABORATORIES LTD. Share Price Today

    Investment Returns

    Over 1 Month 7.43% Over 3 Months 50.79% Over 6 Months 20.97% Over 1 Year 68.69%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    COLINZ LABORATORIES LTD. fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 8.30
    • P/E Ratio (TTM) 16.30
    • Beta 0.20
    • Book Value / share 69.70
    • Return on equity 5.43%
    • EPS (TTM) 4.08
    • Dividend yield [-]%
    • Net profit/quarter (Cr) 0.17
    info icon alternate text

    COLINZ LABORATORIES LTD. Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 1.75
    Operating Expense 1.71
    Net Profit 0.17
    Net Profit Margin (%) 9.71
    Earnings Per Share (EPS) 0.68
    EBITDA 0.27
    Effective Tax Rate (%) 18.18
    Particulars DEC 2025 (Values in Cr)
    Revenue 1.43
    Operating Expense 1.38
    Net Profit 0.08
    Net Profit Margin (%) 5.59
    Earnings Per Share (EPS) 0.33
    EBITDA 0.18
    Effective Tax Rate (%) 30.76
    Particulars SEP 2025 (Values in Cr)
    Revenue 1.39
    Operating Expense 1.36
    Net Profit 0.14
    Net Profit Margin (%) 10.07
    Earnings Per Share (EPS) 0.56
    EBITDA 0.24
    Effective Tax Rate (%) 26.31
    Particulars JUN 2025 (Values in Cr)
    Revenue 1.57
    Operating Expense 1.48
    Net Profit 0.12
    Net Profit Margin (%) 7.64
    Earnings Per Share (EPS) 0.47
    EBITDA 0.21
    Effective Tax Rate (%) 25.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 1.45
    Operating Expense 1.41
    Net Profit 0.15
    Net Profit Margin (%) 10.34
    Earnings Per Share (EPS) 0.60
    EBITDA 0.16
    Effective Tax Rate (%) -25.00
    Particulars MAR 2026 (Values in Cr)
    Revenue 6.14
    Operating Expense 5.93
    Net Profit 0.51
    Net Profit Margin (%) 8.30
    Earnings Per Share (EPS) 2.04
    EBITDA 0.90
    Effective Tax Rate (%) 24.63
    Particulars MAR 2025 (Values in Cr)
    Revenue 6.53
    Operating Expense 6.20
    Net Profit 0.50
    Net Profit Margin (%) 7.65
    Earnings Per Share (EPS) 1.97
    EBITDA 0.79
    Effective Tax Rate (%) 19.35
    Particulars MAR 2024 (Values in Cr)
    Revenue 7.03
    Operating Expense 6.66
    Net Profit 0.49
    Net Profit Margin (%) 6.97
    Earnings Per Share (EPS) 1.93
    EBITDA 0.82
    Effective Tax Rate (%) 24.61
    Particulars MAR 2023 (Values in Cr)
    Revenue 7.15
    Operating Expense 6.72
    Net Profit 0.46
    Net Profit Margin (%) 6.43
    Earnings Per Share (EPS) 1.82
    EBITDA 0.78
    Effective Tax Rate (%) 23.33
    Particulars MAR 2022 (Values in Cr)
    Revenue 6.97
    Operating Expense 6.67
    Net Profit 0.34
    Net Profit Margin (%) 4.87
    Earnings Per Share (EPS) 0.74
    EBITDA 0.76
    Effective Tax Rate (%) 29.16
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 37.61
    ROE % 5.43
    ROCE % 6.72
    Total Debt to Total Equity 0.07
    EBITDA Margin 12.10
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 35.52
    ROE % 5.73
    ROCE % 7.70
    Total Debt to Total Equity 0.05
    EBITDA Margin 11.66
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 32.31
    ROE % 5.81
    ROCE % 7.82
    Total Debt to Total Equity 0.05
    EBITDA Margin 10.91
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 21.69
    ROE % 4.54
    ROCE % 6.78
    Total Debt to Total Equity 0.10
    EBITDA Margin 10.90
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 20.57
    ROE % 2.97
    ROCE % 4.36
    Total Debt to Total Equity 0.10
    EBITDA Margin 8.60
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 5.55
    Total Assets 11.81
    Total Liabilities 11.81
    Total Equity 9.47
    Share Outstanding 0
    Price to Book Ratio 1.93
    Return on Assets (%) 4.20
    Return on Capital (%) 4.91
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 7.00
    Total Assets 11.35
    Total Liabilities 11.35
    Total Equity 8.94
    Share Outstanding 0
    Price to Book Ratio 1.06
    Return on Assets (%) 4.28
    Return on Capital (%) 5.11
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 5.72
    Total Assets 10.23
    Total Liabilities 10.23
    Total Equity 8.13
    Share Outstanding 0
    Price to Book Ratio 1.08
    Return on Assets (%) 4.47
    Return on Capital (%) 5.44
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 5.20
    Total Assets 9.93
    Total Liabilities 9.93
    Total Equity 7.68
    Share Outstanding 0
    Price to Book Ratio 1.09
    Return on Assets (%) 3.41
    Return on Capital (%) 4.15
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 4.68
    Total Assets 10.10
    Total Liabilities 10.10
    Total Equity 7.29
    Share Outstanding 0
    Price to Book Ratio 0.37
    Return on Assets (%) 2.05
    Return on Capital (%) 2.51
    Particulars MAR 2025 (Values in Cr)
    Net Income 0.61
    Cash from Operations -1.24
    Cash from Investing -0.23
    Cash from Financing 0.23
    Net change in Cash -1.45
    Free Cash Flow -0.98
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.65
    Cash from Operations 1.21
    Cash from Investing 0.00
    Cash from Financing 0.22
    Net change in Cash 1.27
    Free Cash Flow 1.21
    Particulars MAR 2023 (Values in Cr)
    Net Income 0.59
    Cash from Operations 0.56
    Cash from Investing 0.00
    Cash from Financing 0.11
    Net change in Cash 0.52
    Free Cash Flow 0.56
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.48
    Cash from Operations 0.61
    Cash from Investing -0.03
    Cash from Financing 0.09
    Net change in Cash 0.52
    Free Cash Flow 0.65
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.24
    Cash from Operations 2.23
    Cash from Investing -0.15
    Cash from Financing 0.08
    Net change in Cash 2.08
    Free Cash Flow 2.39
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 31.48 13.06 1.52 241.24 23.12 38.85
    BLISS GVS PHARMA LTD 509.15 40.93 4.52 5399.85 118.35 552.90
    CIPLA LTD. 1431.65 30.38 3.35 115655.17 1165.55 1672.20
    FERMENTA BIOTECH LTD. 365.50 16.12 2.64 1075.70 256.40 401.20
    GLAXOSMITHKLINE PHARMA LT 2409.90 42.43 18.00 40825.16 2088.00 3343.05
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 31.48 22.01 4.05 241.24 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 538.05 24.12 4.20 1555.54 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8150.15 106.44 23.34 20375.38 7630.00 9850.00
    BLISS GVS PHARMA LTD 509.15 55.04 4.67 5399.85 118.35 552.90

    COLINZ LABORATORIES LTD. shareholding pattern

    Holding
    33.99%
    66.0%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    COLINZ LABORATORIES LTD. Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    68.56 -11.59 redarrow
    red-green-graph indicator
    6 Bearish
    10 Bullish
    • 5 Days 72.20
    • 26 Days 66.90
    • 10 Days 0.00
    • 50 Days 60.90
    • 12 Days 72.20
    • 100 Days 55.70
    • 20 Days 69.10
    • 200 Days 52.70
    66.52 PIVOT
    First Support 66.48 First Resistance 66.54 Second Support 66.46 Second Resistance 66.58 Third Support 66.42 Third Resistance 66.60
    RSI 0.00 ADX 50.57 MACD 5.27 Williams % R -65.25 Commodity Channel Index (CCI) -9.91
    Date 2026-07-08 Week 16496.00 Same Day 1223.00 Month 6937.00
    1 Year 0.21 3 Year 0.34
    Over 1 Month
    7.43% down
    Over 1 Year
    68.69% down
    Over 3 Months
    50.79% down
    Over 3 Years
    22.69% down
    Over 6 Months
    20.97% down
    Over 5 Years
    20.47% down

    COLINZ LABORATORIES LTD. Corporate Actions

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Colinz Laboratories Ltd?

    Answer Field

    Colinz Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 68.56 as on Jul 10 2026 03:29 PM.

    What is the Market Cap of Colinz Laboratories Ltd Share?

    Answer Field

    The market cap of Colinz Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 8.30 as on Jul 10 2026 03:29 PM.

    What is the 52 Week High and Low of Colinz Laboratories Ltd?

    Answer Field

    The 52 Week High and Low of Colinz Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 87.91 and ₹ 36.11.

    What is 1 year return for Colinz Laboratories Ltd?

    Answer Field

    The 1 year returns on the stock has been 79.50%.

    What is the P/E Ratio of Colinz Laboratories Ltd Share?

    Answer Field

    As on Jul 10 2026 03:29 PM the price-to-earnings (PE) ratio for Colinz Laboratories Ltd share is 16.30.

    What is the PB ratio of Colinz Laboratories Ltd Share?

    Answer Field

    As on Jul 10 2026 03:29 PM, the price-to-book (PB) ratio for Colinz Laboratories Ltd share is 69.70.

    How to Buy Colinz Laboratories Ltd Share?

    Answer Field

    You can trade in Colinz Laboratories Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Colinz Laboratories Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Colinz Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Colinz Laboratories Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |